Glycoengineered Monoclonal Antibodies With Homogeneous Glycan (M3, G0, G2, And A2) Using A Chemoenzymatic Approach Have Different Affinities For Fc Gamma Riiia And Variable Antibody-Dependent Cellular Cytotoxicity Activities

Many therapeutic antibodies have been developed, and IgG antibodies have been extensively generated in various cell expression systems. IgG antibodies contain N-glycans at the constant region of the heavy chain (Fc domain), and their N-glycosylation patterns differ during various processes or among cell expression systems. The Fc N-glycan can modulate the effector functions of IgG antibodies, such as antibody-dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). To control Fc N-glycans, we performed a rearrangement of Fc N-glycans from a heterogeneous N-glycosylation pattern to homogeneous N-glycans using chemoenzymatic approaches with two types of endo-beta-N-acetyl glucosaminidases (ENG'ases), one that works as a hydrolase to cleave all heterogeneous N-glycans, another that is used as a glycosynthase to generate homogeneous N-glycans. As starting materials, we used an anti-Her2 antibody produced in transgenic silkworm cocoon, which consists of non-fucosylated pauci-mannose type (Man(2-3)GlcNAc(2)), high-mannose type (Man(4-9)GlcNAc(2)), and complex type (Man(3)GlcNAc(3-4)) N-glycans. As a result of the cleavage of several ENG'ases (endoS, endoM, endoD, endoH, and endoLL), the heterogeneous glycans on antibodies were fully transformed into homogeneous-GlcNAc by a combination of endoS, endoD, and endoLL. Next, the desired N-glycans (M-3; Man(3)-GlcNAc(1), G0; GlcNAc(2)Man(3)GlcNAc(1), G2; Gal(2)GlcNAc(2)Man(3)GlcNAc(1), A2; NeuAc(2)Gal(2)Glc-NAc(2)Man(3)GlcNAc(1)) were transferred from the corresponding oxazolines to the GlcNAcresidue on the intact anti-Her2 antibody with an ENG'ase mutant (endoS-D233Q), and the glycoengineered anti-Her2 antibody was obtained. The binding assay of anti-Her2 antibody with homogenous N-glycans with Fc gamma RIIIa-V158 showed that the glycoform influenced the affinity for Fc gamma RIIIa-V158. In addition, the ADCC assay for the glycoengineered anti-Her2 antibody (mAb-M3, mAb-G0, mAb-G2, and mAb-A2) was performed using SKBR-3 and BT-474 as target cells, and revealed that the glycoform influenced ADCC activity.